| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,830,000 |
| Market
Cap: |
12.55(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.298 - $3.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. is also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
65,403 |
2,581,565 |
| Total Buy Value |
$0 |
$0 |
$90,256 |
$4,837,462 |
| Total People Bought |
0 |
0 |
1 |
9 |
| Total Buy Transactions |
0 |
0 |
2 |
21 |
| Total Shares Sold |
0 |
0 |
3,700 |
4,053,849 |
| Total Sell Value |
$0 |
$0 |
$7,215 |
$12,677,616 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
6 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thackray Helen M. |
SVP Clinical Development, CMO |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
34,500 |
183,115 |
|
- |
|
| King Rachel K. |
President, CEO |
• • – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
96,250 |
452,314 |
|
- |
|
| Hahn Brian M. |
SVP Finance, CFO |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
34,500 |
39,760 |
|
- |
|
| Girard Armand |
SVP, Chief Business Officer |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Magnani John L. |
SVP of Research, CSO |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
34,500 |
324,260 |
|
- |
|
| King Rachel K. |
President, CEO |
• • – |
2020-12-28 |
4 |
AS |
$3.91 |
$329,128 |
D/D |
(84,176) |
356,064 |
|
-41% |
|
| King Rachel K. |
President, CEO |
• • – |
2020-12-28 |
4 |
OE |
$1.12 |
$146,520 |
D/D |
130,821 |
440,240 |
|
- |
|
| Hahn Brian M. |
SVP Finance, CFO |
• – – |
2020-12-16 |
4 |
OE |
$1.12 |
$5,891 |
D/D |
5,260 |
5,260 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2020-11-04 |
4 |
B |
$2.60 |
$3,293,516 |
D/D |
1,266,737 |
630,453 |
2.45 |
17% |
|
| Lampert Mark N |
10% Owner |
– – • |
2020-10-30 |
4 |
B |
$2.75 |
$2,564,683 |
D/D |
932,612 |
544,363 |
2.45 |
18% |
|
| Junius Daniel M |
Director |
– • – |
2020-03-09 |
4 |
B |
$3.40 |
$68,000 |
D/D |
20,000 |
38,000 |
2.39 |
33% |
|
| Magnani John L. |
SVP of Research, CSO |
• – – |
2020-01-06 |
4 |
OE |
$1.12 |
$119,821 |
D/D |
106,983 |
289,760 |
|
- |
|
| Magnani John L. |
SVP of Research, CSO |
• – – |
2019-12-20 |
4 |
OE |
$1.12 |
$119,822 |
D/D |
106,984 |
182,777 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-09-05 |
4 |
B |
$3.18 |
$5,309,950 |
D/D |
1,668,746 |
528,891 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-08-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,455,520 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2019-08-13 |
4 |
B |
$3.18 |
$31,800 |
D/D |
10,000 |
18,000 |
2.39 |
- |
|
| King Rachel K. |
President, CEO |
• • – |
2019-08-06 |
4 |
OE |
$1.12 |
$186,770 |
D/D |
166,759 |
307,144 |
|
- |
|
| Magnani John L. |
SVP of Research, CSO |
• • – |
2018-10-18 |
4 |
AS |
$14.02 |
$49,449 |
D/D |
(3,527) |
75,793 |
|
- |
|
| Magnani John L. |
SVP of Research, CSO |
• • – |
2018-10-17 |
4 |
AS |
$14.00 |
$101,822 |
D/D |
(7,273) |
79,320 |
|
- |
|
| Magnani John L. |
SVP of Research, CSO |
• • – |
2018-10-16 |
4 |
AS |
$14.01 |
$198,942 |
D/D |
(14,200) |
86,593 |
|
- |
|
| Hahn Brian M. |
CFO |
• – – |
2018-06-11 |
4 |
S |
$18.04 |
$348,984 |
D/D |
(19,345) |
0 |
|
- |
|
| Hahn Brian M. |
CFO |
• – – |
2018-06-11 |
4 |
OE |
$1.12 |
$5,891 |
D/D |
5,260 |
19,345 |
|
- |
|
| Magnani John L. |
SVP of Research, CSO |
• • – |
2018-05-23 |
4 |
OE |
$0.33 |
$492 |
D/D |
1,491 |
100,793 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2018-05-10 |
4 |
S |
$17.81 |
$169,890 |
I/I |
(9,539) |
4,995,664 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2018-05-10 |
4 |
OE |
$0.33 |
$169,769 |
I/I |
514,452 |
5,001,197 |
|
- |
|
116 Records found
|
|
Page 3 of 5 |
|
|
